https://doi.org/10.55788/72c2290e
The phase 3 KEYNOTE-590 study (NCT03189719) randomised 749 participants with advanced oesophageal cancer 1:1 to pembrolizumab plus chemotherapy or to placebo plus chemotherapy. The primary results displayed a clear efficacy benefit for participants in the pembrolizumab group [1]. Now, Prof. Manish Shah (Weill Cornell Medicine, NY, USA) presented the 5-year outcomes of the trial [2].
“Pembrolizumab added to chemotherapy continued to display a benefit in OS compared with chemotherapy plus placebo, with 5-year OS rates of 10.6% and 3.0%,” said Prof. Shah. The median OS was 12.3 months in the experimental arm and 9.8 months in the control arm (HR 0.72; 95% CI 0.62–0.84). This result was consistent in the subpopulations of participants with a combined positive score (CPS) ≥10 (n=383) and those with squamous cell carcinomas (n=549). Furthermore, the median progression-free survival was 6.3 months in the pembrolizumab arm and 5.8 months in the placebo arm (HR 0.64; 95% CI 0.54–0.75). “We also noticed numerical benefits in patients on pembrolizumab with respect to dysphagia, pain, and reflux,” mentioned Prof. Shah.
There were no substantial differences in the safety profiles of the 2 treatment regimens, according to Prof. Shah. However, immune-mediated adverse events and infusion reactions appeared to occur somewhat more frequently in the pembrolizumab arm (27.3% vs 15.7%).
Overall, the 5-year results of KEYNOTE-590 continue to support the use of pembrolizumab plus chemotherapy as first-line therapy in patients with advanced oesophageal cancer.
- Sun JM, et al. Lancet. 2021;398(10302):759-771.
- Shah MA, et al. First-line pembrolizumab plus chemotherapy for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. Abstract 250, ASCO Gastrointestinal Cancers Symposium 2024, 18–20 January, San Francisco, CA, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« New standard-of-care for locally advanced oesophageal squamous cell carcinoma? Next Article
Thoracoscopic oesophagectomy non-inferior to open surgery in thoracic oesophageal cancer »
« New standard-of-care for locally advanced oesophageal squamous cell carcinoma? Next Article
Thoracoscopic oesophagectomy non-inferior to open surgery in thoracic oesophageal cancer »
Related Articles
March 12, 2021
COVID-19 impact on gastrointestinal cancer care
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com